179 related articles for article (PubMed ID: 15023041)
1. Flow cytometric analysis of CD5+ B cells: a frame of reference for minimal residual disease analysis in chronic lymphocytic leukemia.
Gupta R; Jain P; Deo SV; Sharma A
Am J Clin Pathol; 2004 Mar; 121(3):368-72. PubMed ID: 15023041
[TBL] [Abstract][Full Text] [Related]
2. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
3. Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.
Durrieu F; Geneviève F; Arnoulet C; Brumpt C; Capiod JC; Degenne M; Feuillard J; Garand R; Kara-Terki A; Kulhein E; Maynadié M; Ochoa-Noguera ME; Plesa A; Roussel M; Eghbali H; Truchan-Graczyk M; de Carvalho Bittencourt M; Feugier P; Béné MC
Cytometry B Clin Cytom; 2011 Nov; 80(6):346-53. PubMed ID: 21976156
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders.
Cabezudo E; Carrara P; Morilla R; Matutes E
Haematologica; 1999 May; 84(5):413-8. PubMed ID: 10329919
[TBL] [Abstract][Full Text] [Related]
5. Comparative flow cytometric evaluation of bcl-2 oncoprotein in CD5+ and CD5- B-cell lymphoid chronic leukemias.
Molica S; Mannella A; Crispino G; Dattilo A; Levato D
Haematologica; 1997; 82(5):555-9. PubMed ID: 9407720
[TBL] [Abstract][Full Text] [Related]
6. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
7. Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination.
Rutella S; Rumi C; Puggioni P; Barberi T; Di Mario A; Larocca LM; Leone G
Haematologica; 1999 May; 84(5):419-24. PubMed ID: 10329920
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells.
Wang L; Abbasi F; Gaigalas AK; Vogt RF; Marti GE
Cytometry B Clin Cytom; 2006 Nov; 70(6):410-5. PubMed ID: 16967494
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).
Sokol L; Agosti SJ
Am J Hematol; 2004 Feb; 75(2):107-9. PubMed ID: 14755378
[TBL] [Abstract][Full Text] [Related]
10. [Expression of proliferation marker Ki 67 in chronic lymphocytic leukemia].
Diop S; Letestu R; Orsolani D; Leboeuf Y; Le Tutour P; Thiam D; Diakhate L; Valensi F
Dakar Med; 2005; 50(2):65-8. PubMed ID: 16295759
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic characterization of the leukemic B-cells from Iranian patients with chronic lymphocytic leukemia: association between CD38 expression and disease progression.
Hojjat Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Shamsian Khoramabadi A; Rabbani H; Shokri F
Iran J Immunol; 2008 Mar; 5(1):25-35. PubMed ID: 18319522
[TBL] [Abstract][Full Text] [Related]
12. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
13. Reactivity of monoclonal antibodies OK-CLL (anti-CD5) with peripheral blood cells of patients with B cell lymphoproliferative disorders.
Milosević D; Marinković M; Jelić S; Colović M; Spuzić I
Arch Immunol Ther Exp (Warsz); 1995; 43(1):23-9. PubMed ID: 8744680
[TBL] [Abstract][Full Text] [Related]
14. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C; Lin K; Pettitt AR; Kneba M; Montserrat E; Cymbalista F; Hallek M; Hillmen P; Ghia P;
Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia.
Allgeier T; Garhammer S; Nössner E; Wahl U; Kronenberger K; Dreyling M; Hallek M; Mocikat R
Cancer Lett; 2007 Jan; 245(1-2):275-83. PubMed ID: 16516377
[TBL] [Abstract][Full Text] [Related]
16. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.
Garcia Vela J; Delgado I; Benito L; Monteserin M; Garcia Alonso L; Somolinos N; Andreu M; Oña F
Leukemia; 1999 Oct; 13(10):1501-5. PubMed ID: 10516749
[TBL] [Abstract][Full Text] [Related]
17. Use of image analysis and immunostaining of bone marrow trephine biopsy specimens to quantify residual disease in patients with B-cell chronic lymphocytic leukemia.
Gala JL; Guiot Y; Delannoy A; Scheiff JM; Philippe M; Martiat P
Mod Pathol; 1999 Apr; 12(4):391-9. PubMed ID: 10229504
[TBL] [Abstract][Full Text] [Related]
18. Significant CD5 expression on normal stage 3 hematogones and mature B Lymphocytes in bone marrow.
Fuda FS; Karandikar NJ; Chen W
Am J Clin Pathol; 2009 Nov; 132(5):733-7. PubMed ID: 19846815
[TBL] [Abstract][Full Text] [Related]
19. Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them.
Böhm I
Biomed Pharmacother; 2004 Jun; 58(5):338-43. PubMed ID: 15194170
[TBL] [Abstract][Full Text] [Related]
20. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.
Huh YO; Keating MJ; Saffer HL; Jilani I; Lerner S; Albitar M
Am J Clin Pathol; 2001 Sep; 116(3):437-43. PubMed ID: 11554173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
